2.24  0.05 (2.28%)		04-25 16:00
Open: 2.15 High: 2.26 Volume: 29,454		Pre. Close: 2.19 Low: 2.15 Market Cap: 36(M)

Short term
Mid term
Targets	6-month :	3.08	1-year :	3.53
Resists	First :	2.64	Second :	3.02
Pivot price	2.41
Supports	First :	2	Second :	1.67
MAs	MA(5) :	2.19	MA(20) :	2.51
	MA(100) :	3.65	MA(250) :	5.05
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	24.1	D(3) :	21
RSI	RSI(14): 39.9
52-week	High :	7.59	Low :	2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BCTX ] has closed above bottom band by 34.1%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.26 - 2.27	2.27 - 2.28
Low:	2.12 - 2.14	2.14 - 2.15
Close:	2.22 - 2.24	2.24 - 2.26

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Thu, 07 Mar 2024
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ... - GlobeNewswire

Wed, 07 Feb 2024
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case - GlobeNewswire

Tue, 06 Feb 2024
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP ... - Yahoo Finance

Tue, 30 Jan 2024
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - Yahoo Finance

Thu, 30 Nov 2023
Vancouver biotech BriaCell reports tumour shrinkage in clinical trials - Business in Vancouver

Sun, 10 Sep 2023
BriaCell (BCTX): Poised To Move To Advanced Trials, But An Unconvincing Thesis - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	16 (M)
Shares Float	12 (M)
Held by Insiders	12.2 (%)
Held by Institutions	13.7 (%)
Shares Short	678 (K)
Shares Short P.Month	796 (K)

EPS	-0.8
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-85.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.99
Qtrly Earnings Growth	0 %
Operating Cash Flow	-31 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-2.84
PEG Ratio	0
Price to Book value	-4.49
Price to Sales	0
Price to Cash Flow	-1.15

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.